{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:13Z","timestamp":1793656513755,"version":"4.5.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic tumor volume (MTV) assessed using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography, a measure of tumor burden, is a promising prognostic indicator in large B-cell lymphoma (LBCL). This exploratory analysis evaluated relationships between baseline MTV (categorized as low [median or less] vs high [greater than median]) and clinical outcomes in the phase 3 ZUMA-7 study (NCT03391466). Patients with LBCL relapsed within 12 months of or refractory to first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel (axi-cel; autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard care (2-3 cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transplantation in patients who had a response). All P values are descriptive. Within high- and low-MTV subgroups, event-free survival (EFS) and progression-free survival (PFS) were superior with axi-cel vs standard care. EFS in patients with high MTV (vs low MTV) was numerically shorter with axi-cel and was significantly shorter with standard care. PFS was shorter in patients with high MTV vs low MTV in both the axi-cel and standard-care arms, and median MTV was lower in patients in ongoing response at data cutoff vs others. Median MTV was higher in patients treated with axi-cel who experienced grade \u22653 neurologic events or cytokine release syndrome (CRS) than in patients with grade 1\/2 or no neurologic events or CRS, respectively. Baseline MTV less than or equal to median was associated with better clinical outcomes in patients receiving axi-cel or standard care for second-line LBCL. The trial was registered at www.clinicaltrials.gov as #NCT03391466.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021620","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:07:11Z","timestamp":1711991231000},"page":"2464-2473","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"first","affiliation":[{"name":"1Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Cancer Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-320X","authenticated-orcid":false,"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"4University of Paris, H\u00f4pital Saint-Louis, Hemato-Oncology, DMU DHI, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"5Department of Hematology, University of Lille, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[{"name":"7The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Vardhanabhuti","sequence":"additional","affiliation":[{"name":"8Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Winters","sequence":"additional","affiliation":[{"name":"8Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Filosto","sequence":"additional","affiliation":[{"name":"8Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-8072","authenticated-orcid":false,"given":"Christina","family":"To","sequence":"additional","affiliation":[{"name":"8Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[{"name":"8Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schupp","sequence":"additional","affiliation":[{"name":"8Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-5749","authenticated-orcid":false,"given":"Ronald","family":"Korn","sequence":"additional","affiliation":[{"name":"9Imaging Endpoints, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"10Amsterdam University Medical Center (location University of Amsterdam), Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2024061315210423600_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2024061315210423600_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024061315210423600_bib3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10343","key":"2024061315210423600_bib4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"2024061315210423600_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024061315210423600_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"16 suppl","key":"2024061315210423600_bib7","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2022.40.16_suppl.7565","article-title":"Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"40","author":"Locke","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024061315210423600_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","article-title":"Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"8","key":"2024061315210423600_bib9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1097-0142(19880415)61:8<1719::AID-CNCR2820610834>3.0.CO;2-A","article-title":"Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment","volume":"61","author":"Specht","year":"1988","journal-title":"Cancer"},{"issue":"5","key":"2024061315210423600_bib10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1200\/JCO.2001.19.5.1388","article-title":"Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance","volume":"19","author":"Gobbi","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024061315210423600_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1874471015666220329120631","article-title":"Methodological aspects and the prognostic value of metabolic tumor volume assessed with 18F-FDG PET\/CT in lymphomas","volume":"15","author":"Tutino","year":"2022","journal-title":"Curr Radiopharm"},{"issue":"5","key":"2024061315210423600_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024061315210423600_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024061315210423600_bib14","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 7","key":"2024061315210423600_bib15","doi-asserted-by":"crossref","first-page":"vii78","DOI":"10.1093\/annonc\/mds273","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Tilly","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"2024061315210423600_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","article-title":"Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement","volume":"91","author":"Song","year":"2012","journal-title":"Ann Hematol"},{"issue":"7","key":"2024061315210423600_bib17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2024061315210423600_bib18","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","article-title":"SAKK38\/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model","volume":"4","author":"Ceriani","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2024061315210423600_bib19","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"2024061315210423600_bib20","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024061315210423600_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10428194.2021.1966786","article-title":"Prognostic value of presalvage metabolic tumor volume in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"63","author":"Alderuccio","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2024061315210423600_bib22","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2024061315210423600_bib23","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2024061315210423600_bib24","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"8","key":"2024061315210423600_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","article-title":"Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells","volume":"46","author":"Sesques","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2024061315210423600_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40644-022-00513-y","article-title":"Whole body FDG PET\/MR for progression free and overall survival prediction in patients with relapsed\/refractory large B-cell lymphomas undergoing CAR T-cell therapy","volume":"22","author":"Sj\u00f6holm","year":"2022","journal-title":"Cancer Imaging"},{"issue":"20","key":"2024061315210423600_bib27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2024061315210423600_bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","article-title":"Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma","volume":"45","author":"Toledano","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2024061315210423600_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"2024061315210423600_bib30","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024061315210423600_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2022-158492","article-title":"Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in ZUMA-7","volume":"140","author":"Locke","year":"2022","journal-title":"Blood"},{"key":"2024061315210423600_bib32","doi-asserted-by":"crossref","first-page":"974029","DOI":"10.3389\/fonc.2022.974029","article-title":"Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment","volume":"12","author":"Winkelmann","year":"2022","journal-title":"Front Oncol"},{"issue":"19","key":"2024061315210423600_bib33","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axi-cel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024061315210423600_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/0971-3026.125626","article-title":"FDG-PET\/CT in lymphoma","volume":"23","author":"D'Souza","year":"2013","journal-title":"Indian J Radiol Imaging"},{"issue":"7","key":"2024061315210423600_bib35","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","article-title":"Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study","volume":"107","author":"Kostakoglu","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2024061315210423600_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"2024061315210423600_bib37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-022-06075-2","article-title":"Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"50","author":"Winkelmann","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2024061315210423600_bib38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"2024061315210423600_bib39","doi-asserted-by":"crossref","first-page":"713577","DOI":"10.3389\/fonc.2021.713577","article-title":"Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"2024061315210423600_bib40","doi-asserted-by":"crossref","first-page":"994520","DOI":"10.3389\/fimmu.2023.994520","article-title":"Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers","volume":"14","author":"Choi","year":"2023","journal-title":"Front Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/24\/2464\/2228958\/blood_bld-2023-021620-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/24\/2464\/2228958\/blood_bld-2023-021620-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:26:04Z","timestamp":1718292364000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/24\/2464\/515553\/Axicabtagene-ciloleucel-vs-standard-of-care-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":40,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021620","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}